Exosomes – the latest in cell based hair restoration technologies since Platelet Rich Plasma hair treatment. It has been suggested that Exosomes function as stem cells building blocks that may hold the promise in promoting healthy hair growth. Can Exosomes pave the way for the next generation in minimally invasive cell based hair restotation? Check out Exosomes hair therapy for details.
Hair restoration news – Dr. Tsuji stem cell hair multiplication research will likely be the one that wins the race for a real hair loss cure, according to many in our community. Find out what is so unique about Dr. Tsuji’s hair multiplication research and why many believe that this is the treatment we have all been waiting for. Click Dr Tsuji hair multiplication news for details.
News update on Samumed WNT pathway activator hair loss treatment. Wnt pathway has been extensively studied in recent years and has been implicated in many degenerative diseases and conditions including androgenetic alopecia or pattern baldness in men and women. Samumed, one of the leading biotech companies in Wnt pathway modulation has officially started their phase 2/3 trial for SM04554 for the treatment of androgenetic alopecia. Click Samumed WNT Pathway Activator Hair Loss Treatment for the latest updates and anticipated commercial availability date.
RT1640 Hair Loss Cure? RiverTown Therapeutics’ remarkable 14 weeks before and after patient result sparks extreme interests in our forum community. Could this experimental topical formula be the hair loss cure we are hoping for? The developer of this new product mentioned that one of the key ingredients has been tested in over 600 humans in FDA sanctioned clinical trials already. So how soon can we see this product on the market? Click RiverTown RT1640 Hair Loss Cure for our coverage.
Hair restoration news: WAY-316606 baldness cure from osteoporosis drug? Possibly the biggest news in 2018 for hair restoration research. Possibility of a hair loss cure found in an existing drug compound WAY-316606 that is prsently used for treatment of osteoporosis. Researchers at Manchester University discovered huge potential for WAY-316606 to be developed into a baldness cure that is very effective and with few side effects. Experiments have already been performed using human hair follicles and the results are impressive. Click WAY-316606 Baldness Cure to read the full article.
Hair Restoration News – Korean hair researchers discovered CXXC5 protein inside of a cell that can negatively impact WNT signaling pathways and ultimately affect hair regrowth and hair follicle development in adults. By using a new PTD-DBM hair regeneration biochemical compound, the researchers were able to inhibit the negative activity of CXXC5 protein on WNT signaling pathways and ultimate stimulate hair growth. Click PTD-DBM CXXC5 Hair Regrowth to read full article on this groundbreaking story.
Hair Restoration News: Lactate Influences Hair Follicle Stem Cells. New study suggests that Lactate may influence hair follicle stem cells in a dose dependent manner. What is Lactate? Lactate regulates human metabolism and is known for being able to stimulate collagen synthesis and vessel growth. Lately it has been shown that lactate, in vivo, may have a role to play in the proliferation of stem cells. Click Lactate Influences Hair Follicle Stem Cells for complete coverage on this topic and our community discussion.
For those who are new to our community: RCH-01 is a cell based hair restoration procedure using dermal sheath cup (DSC) cells harvested from the patient's donor follicles, usually from the back of the patient's scalp. The harvested cells will then be multiplied and injected into the balding areas of the patient's scalp. If successful, this treatment could potentially eliminate the need for invasive hair transplant surgery. Here we have the latest update from RepliCel RCH-01 cell based hair loss treatment - 2017 forecast.
World renowned researcher Angela M. Christiano, PhD and colleagues found that Janus kinase (JAK) inhibitors promote hair growth when directly applied to the skin in mouse and human hair follicles study. Two JAK inhibitors Ruxolitinib and Tofacitinib have already been approved by the US FDA for the treatment of blood diseases and rheumatoid arthritis respectively.